These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39180611)

  • 1. Risk factor for hypofibrinogenemia induced by tocilizumab in rheumatic diseases.
    Bao Z; Xu X
    Clin Rheumatol; 2024 Oct; 43(10):3263-3264. PubMed ID: 39180611
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia.
    An Q; Ma R; Yuan D; Huang J; Luo J; Wang Y; Pan Y; Wang P; Lv X; Pu D; He L
    Clin Rheumatol; 2024 May; 43(5):1491-1501. PubMed ID: 38494557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab-induced hypofibrinogenemia: A report of 7 cases.
    Martis N; Chirio D; Queyrel-Moranne V; Zenut MC; Rocher F; Fuzibet JG
    Joint Bone Spine; 2017 May; 84(3):369-370. PubMed ID: 27324602
    [No Abstract]   [Full Text] [Related]  

  • 4. Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review.
    Üsküdar Cansu D; Demirtaş E; Andiç N; Üsküdar Teke H; Korkmaz C
    Rheumatol Int; 2019 Apr; 39(4):743-750. PubMed ID: 30874871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
    Furst DE; Keystone EC; So AK; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Rubbert-Roth A; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop KL
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii2-34. PubMed ID: 23532441
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety issues of biologics in pregnant patients with rheumatic diseases.
    Ostensen M
    Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
    Espinoza F; Le Blay P; Combe B
    J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
    Nolan TJ; O'Connor MB; Bond U; Swan J; Phelan MJ
    Rheumatol Int; 2013 Jul; 33(7):1907-8. PubMed ID: 22441967
    [No Abstract]   [Full Text] [Related]  

  • 9. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis.
    Hakala M; Immonen K; Korpela M; Vasala M; Kauppi MJ
    Ann Rheum Dis; 2013 Mar; 72(3):464-5. PubMed ID: 23148310
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
    Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies.
    Perl M; Herfeld K; Harrer DC; Höpting M; Schweiger M; Sterz U; Knödler L; Heimerl S; Hansmann L; Herr W; Poeck H; Wolff D; Edinger M; Hart C; Fante MA
    Haematologica; 2024 Sep; 109(9):2969-2977. PubMed ID: 38546698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.
    Régnier-Rosencher E; Farhi D; Lebrun A; Salliot C; Dougados M; Dupin N
    Dermatology; 2012; 224(1):72-83. PubMed ID: 22487697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis.
    Sakaue S; Sumitomo S; Kubo K; Fujio K; Yamamoto K
    Rheumatology (Oxford); 2014 Aug; 53(8):1529-30. PubMed ID: 24609062
    [No Abstract]   [Full Text] [Related]  

  • 15. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment.
    Sartori NS; Picon P; Papke A; Neyeloff JL; da Silva Chakr RM
    PLoS One; 2019; 14(12):e0224963. PubMed ID: 31790428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series.
    Serling-Boyd N; Mohareb AM; Kim AY; Hyle EP; Wallace ZS
    Ann Rheum Dis; 2021 Feb; 80(2):274-276. PubMed ID: 32732241
    [No Abstract]   [Full Text] [Related]  

  • 17. Psoriasis onset with tocilizumab.
    Grasland A; Mahé E; Raynaud E; Mahé I
    Joint Bone Spine; 2013 Oct; 80(5):541-2. PubMed ID: 23731639
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis.
    Rocchi V; Puxeddu I; Cataldo G; Del Corso I; Tavoni A; Bazzichi L; Bombardieri S; Migliorini P
    Rheumatology (Oxford); 2014 Aug; 53(8):1527-9. PubMed ID: 24899663
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.
    Bradford RD; Pettit AC; Wright PW; Mulligan MJ; Moreland LW; McLain DA; Gnann JW; Bloch KC
    Clin Infect Dis; 2009 Sep; 49(6):924-7. PubMed ID: 19681709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.